Study of a new drug for bronchiectasis with chronic pseudomonas infection
Part of Lungs & breathing clinical trials.
This study tests an investigational drug given through an IV to see if it can reduce lung infections and flare-ups in people with bronchiectasis who have a chronic pseudomonas infection. Participation may help improve symptoms and quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 12 years or older and weigh at least 35 kg.
- You need a confirmed diagnosis of bronchiectasis (widened airways in the lungs) by a CT scan.
- You have had at least 2 moderate or 1 severe flare-up in the past year that required antibiotics.
- You have been stable (no flare-up) for at least 4 weeks before starting the study.
- You have evidence of pseudomonas bacteria in your lungs within the last 2 years, and a positive sputum test within 5 weeks before starting the study.
- You are not currently on long-term oxygen therapy, and you do not have certain other lung conditions or active infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medication called AZD0292 for people with bronchiectasis who have a long-term Pseudomonas infection. It aims to see if the drug can reduce flare-ups and improve lung health.
This trial tests a new drug called CTX-187 in two groups: healthy volunteers (Parts A and B) and people with chronic lung infection from bronchiectasis (Part C). It helps find the right dose and checks safety.
This trial tests whether a new medication, BI 1291583, can help people with bronchiectasis reduce lung infections and symptoms. You may join if you have had at least one or two lung flare-ups in the past year.
This trial tests two different antibiotic treatments for adults with bronchiectasis who have a new or recent infection with Pseudomonas aeruginosa (PA) bacteria in their airways. The goal is to see which regimen works better to clear the infection early.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This trial tests a new drug called AZD6793 for people with moderate to very severe COPD. It aims to see if the drug can help improve breathing and reduce flare-ups.
Hear when a new Bronchiectasis With Pseudomonas Aeruginosa Colonization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.